首页
400-620-6333
切换导航
搜索
基本描述
| 英文名称 | anizatrectinib |
|---|---|
| 别名 | BLN64892;hTrkA-IN-1 |
| 英文别名 | BLN64892;hTrkA-IN-1 |
名称和标识符
| INCHI | InChI=1S/C29H32FN7O2/c1-19-27(22-15-31-20(2)32-16-22)35-37(24-10-5-4-6-11-24)28(19)34-29(38)33-26-18-36(12-13-39-3)17-25(26)21-8-7-9-23(30)14-21/h4-11,14-16,25-26H,12-13,17-18H2,1-3H3,(H2,33,34,38)/t25-,26+/m0/s1 |
|---|---|
| InChi Key | BGKSBHPSVMJTFL-IZZNHLLZSA-N |
| Canonical SMILES | Fc1cc(ccc1)[C@H]1[C@@H](CN(C1)CCOC)NC(=O)Nc1c(c(nn1c1ccccc1)c1cnc(nc1)C)C |
| PubChem CID | 92135967 |
数据库链接
| PubChem CID | 92135967 |
|---|---|
| CAS Registry No. | 1824664-89-2 |
关联配体
| Ligand ID | 12087 |
|---|---|
| 名称 | anizatrectinib |
| 别名 | hTrkA-IN-1 |
| 类别 | Synthetic organic |
| 学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide |
| 生物活性评价 |
In a KinaseProfiler™ screening assay anizatrectinib (10 μΜ) almost completely inhibited TrkA and TrkB kinase activity, with very few predicted off-targets |
| 评价 |
We obtained the chemical structure for anizatrectinib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a tyrosine kinase inhibitor and antineoplastic. It is a potent and orally active inhibitor of TrkA kinase, and its structuire and use are claimed in patent WO2015175788A1 |
产品问答
产品问答
上海阿拉丁生化科技股份有限公司
? 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任
危险品化学品经营许可证（带存储）